Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Miklos EgyedSandor LueffJudit BorbelyArpad IllesPublished in: Future oncology (London, England) (2022)
Bruton's tyrosine kinase inhibitors have changed the treatment landscape for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and lymphoplasmacytic lymphoma dramatically. In 2019, acalabrutinib was approved by the US FDA for the treatment of treatment-naive and relapsed/refractory CLL and MCL. Acalabrutinib monotherapy was found to be effective and safe in CLL patients. In ASCEND and ELEVATE treatment-naive studies, acalabrutinib monotherapy and the combination with obinutuzumab demonstrated improved efficacy and an acceptable safety profile. The triple combination with venetoclax showed a high rate of molecular remission without an impaired safety profile. Adverse events, with an occurrence rate of >20%, were as follows: grade 1-2 myelosuppression, gastrointestinal toxicity, rash, constitutional symptoms; grade 3 or 4 toxicities were syncope, pneumonia, hypertension, atrial fibrillation, neutropenia and thrombocytopenia.
Keyphrases
- chronic lymphocytic leukemia
- atrial fibrillation
- combination therapy
- clinical trial
- systemic lupus erythematosus
- diffuse large b cell lymphoma
- intensive care unit
- ejection fraction
- physical activity
- chronic kidney disease
- acute coronary syndrome
- newly diagnosed
- extracorporeal membrane oxygenation
- venous thromboembolism
- pulmonary embolism
- direct oral anticoagulants
- catheter ablation
- mechanical ventilation
- patient reported outcomes
- oral anticoagulants
- study protocol